NASDAQ:TVRD Tvardi Therapeutics (TVRD) Stock Price, News & Analysis $4.97 -0.19 (-3.68%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tvardi Therapeutics Stock (NASDAQ:TVRD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tvardi Therapeutics alerts:Sign Up Key Stats Today's Range$4.90▼$5.1650-Day Range$5.16▼$42.9852-Week Range$4.90▼$43.65Volume259,684 shsAverage Volume96,983 shsMarket Capitalization$46.62 millionP/E RatioN/ADividend YieldN/APrice Target$55.50Consensus RatingHold Company Overview Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. Read More Tvardi Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreTVRD MarketRank™: Tvardi Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 475th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingTvardi Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 3 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialTvardi Therapeutics has a consensus price target of $55.50, representing about 1,014.5% upside from its current price of $4.98.Amount of Analyst CoverageTvardi Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tvardi Therapeutics' stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.81% of the float of Tvardi Therapeutics has been sold short.Short Interest Ratio / Days to CoverTvardi Therapeutics has a short interest ratio ("days to cover") of 20.6, which indicates bearish sentiment.Change versus previous monthShort interest in Tvardi Therapeutics has recently increased by 26.02%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTvardi Therapeutics does not currently pay a dividend.Dividend GrowthTvardi Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.81% of the float of Tvardi Therapeutics has been sold short.Short Interest Ratio / Days to CoverTvardi Therapeutics has a short interest ratio ("days to cover") of 20.6, which indicates bearish sentiment.Change versus previous monthShort interest in Tvardi Therapeutics has recently increased by 26.02%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.46 News SentimentTvardi Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Tvardi Therapeutics this week, compared to 3 articles on an average week.Search Interest15 people have searched for TVRD on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows4 people have added Tvardi Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tvardi Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.10% of the stock of Tvardi Therapeutics is held by insiders.Percentage Held by Institutions44.66% of the stock of Tvardi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tvardi Therapeutics' insider trading history. Receive TVRD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tvardi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TVRD Stock News HeadlinesFaruqi & Faruqi Reminds Tvardi Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 3, 2025 - TVRDOctober 23 at 1:05 PM | prnewswire.comFY2025 EPS Estimates for TVRD Boosted by Cantor FitzgeraldOctober 18, 2025 | americanbankingnews.comNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor Green, it's a bill that contains "the entire setup, groundwork and infrastructure to move from cash to digital currency."October 24 at 2:00 AM | Goldco Precious Metals (Ad)Tvardi Therapeutics (NASDAQ:TVRD) Research Coverage Started at BarclaysOctober 16, 2025 | americanbankingnews.comTvardi Therapeutics (NASDAQ:TVRD) Stock Rating Lowered by Raymond James FinancialOctober 16, 2025 | americanbankingnews.comTvardi Therapeutics (NASDAQ:TVRD) Earns "Sell (E+)" Rating from Weiss RatingsOctober 16, 2025 | americanbankingnews.comTVRD SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsOctober 15, 2025 | prnewswire.comBTIG Research Has Lowered Expectations for Tvardi Therapeutics (NASDAQ:TVRD) Stock PriceOctober 15, 2025 | americanbankingnews.comSee More Headlines TVRD Stock Analysis - Frequently Asked Questions How have TVRD shares performed this year? Tvardi Therapeutics' stock was trading at $29.09 on January 1st, 2025. Since then, TVRD shares have decreased by 82.9% and is now trading at $4.98. How were Tvardi Therapeutics' earnings last quarter? Tvardi Therapeutics, Inc. (NASDAQ:TVRD) posted its quarterly earnings data on Thursday, August, 14th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.49. Tvardi Therapeutics had a negative net margin of 678.79% and a negative trailing twelve-month return on equity of 565.83%. How do I buy shares of Tvardi Therapeutics? Shares of TVRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2025Today10/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TVRD Previous SymbolNASDAQ:TVRD CIK1346830 WebN/A Phone(203) 406-3700Fax203-567-1510Employees80Year Founded2004Price Target and Rating Average Price Target for Tvardi Therapeutics$55.50 High Price Target$78.00 Low Price Target$15.00 Potential Upside/Downside+1,014.5%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$70.87 million Net Margins-678.79% Pretax Margin-453.48% Return on Equity-565.83% Return on Assets-66.71% Debt Debt-to-Equity RatioN/A Current Ratio4.04 Quick Ratio4.04 Sales & Book Value Annual Sales$7.14 million Price / Sales6.54 Cash FlowN/A Price / Cash FlowN/A Book Value($3.02) per share Price / Book-1.65Miscellaneous Outstanding Shares9,380,000Free Float9,086,000Market Cap$46.71 million OptionableN/A Beta0.24 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:TVRD) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredTrade this between 9:30 and 10:45 am ESTIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBitcoin is dead?Bitcoin’s historic run may be ending — and Weiss Ratings’ Juan Villaverde, who’s nailed every major crypto bul...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tvardi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tvardi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.